The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab monotherapy is used for first-line treatment of advanced NSCLC in patients with a tumor proportion score (TPS) for programmed death ligand 1 (PD-L1) of 50% or greater. Here, PDCD1 is linked to neoplasm.